Lilly再出手，5.75亿美元收购肿瘤药企业AurKa Pharma，获得Aurora激酶抑制剂AK-01

The acquisition of AurKa Pharma supports Lilly's external innovation strategy, in which we seek to partner with leading life science venture capital firms in order to identify, support and access promising innovation in areas of unmet medical need. We are excited with the value TVM created for this compound through its early-Phase studies, and we look forward to more opportunities in the future.

Through the unique healthcare venture capital model pioneered by TVM Capital Life Science, companies such as AurKa have been established to more quickly and efficiently bring promising compounds to clinical proof-of-concept. We are pleased that the scientific advances made by AurKa could contribute to the development of AK-01 and hopefully help deliver a potential new medicine for cancer patients.